High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. First, what is the current role of stem cell transplantation (SCT) in comparison with standard-dose therapy incorporating novel agents? Second, should ASCT be performed upfront (“early”) or later (“delayed”) in the course of the disease? Third, should single or double ASCT be performed? Fourth, is allogeneic SCT still an option for patients with MM? This article provides an overview of available data and evidence-based responses regarding the role of SCT in MM.
Is there still a role for stem cell transplantation in multiple myeloma?
Mina R.
First
;
2019-01-01
Abstract
High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. First, what is the current role of stem cell transplantation (SCT) in comparison with standard-dose therapy incorporating novel agents? Second, should ASCT be performed upfront (“early”) or later (“delayed”) in the course of the disease? Third, should single or double ASCT be performed? Fourth, is allogeneic SCT still an option for patients with MM? This article provides an overview of available data and evidence-based responses regarding the role of SCT in MM.File | Dimensione | Formato | |
---|---|---|---|
[Publisher Version] Mina_Lonial -2019 Is there still a role-Cancer.pdf
Accesso riservato
Descrizione: [Restricted access - Published Vsn.] Mina R and Lonial S. Cancer . 2019 Aug 1;125(15):2534-2543. doi: 10.1002/cncr.32060. Epub 2019 Apr 15. © 2019 American Cancer Society. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32060 | https://doi.org/10.1002/cncr.32060
Tipo di file:
PDF EDITORIALE
Dimensione
298.97 kB
Formato
Adobe PDF
|
298.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
[Author Vsn] Mina and Lonial - 2019 - Cancer - Is there still a role for ASCT b.pdf
Open Access dal 03/08/2020
Descrizione: [Author Vsn.] Mina R and Lonial S. Cancer . 2019 Aug 1;125(15):2534-2543. doi: 10.1002/cncr.32060. Epub 2019 Apr 15. © 2019 American Cancer Society. The published version is available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32060 | https://doi.org/10.1002/cncr.32060
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
437.19 kB
Formato
Adobe PDF
|
437.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.